Oncolytics Biotech to Discuss Pivotal Anal Cancer Study with FDA
ONCY has more than doubled off its 52-week low of $0.326.
Summary
Oncolytics Biotech has scheduled a Type C meeting with the FDA to discuss plans for a single-arm pivotal study of pelareorep in anal cancer, a crucial step towards potential regulatory approval.
Key Events · Product Development and Regulatory · ONCY
-
FDA Type C Meeting Scheduled
Oncolytics Biotech announced a Type C meeting with the FDA on April 16, 2026, to discuss a single-arm pivotal study for pelareorep in squamous cell anal carcinoma (SCAC).
-
Potential Registrational Pathway
The meeting aims to align on a study design for a potential full approval of pelareorep in combination with a checkpoint inhibitor for second-line and later SCAC patients, who currently lack alternative approved therapies.
-
Encouraging Clinical Data
Pelareorep previously demonstrated a 30% objective response rate (ORR) and 17-month median duration of response in late-line SCAC patients in the GOBLET study, significantly outperforming real-world outcomes.
-
Strategic Importance Amidst Financial Challenges
This positive clinical development is crucial for the company, which recently disclosed a going concern warning and filed a $250 million universal shelf registration, potentially bolstering investor confidence and future financing efforts.
Analysis · ONCY · Life Sciences
Oncolytics Biotech's announcement of a Type C meeting with the FDA to discuss a single-arm pivotal study for pelareorep in squamous cell anal carcinoma (SCAC) is a critical development. For a clinical-stage biotech, advancing a drug towards a registrational pathway is a major value driver. This news is particularly significant given the company's recent disclosure of a going concern warning in its 10-K and the filing of a $250 million universal shelf registration. Positive clinical progress, supported by encouraging prior data, could improve investor sentiment and facilitate future capital raises necessary for the company's operations.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ONCY was trading at $0.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $96.4M. The 52-week trading range was $0.33 to $1.51. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.